| 前收盘价格 | 13.30 |
| 收盘价格 | 13.28 |
| 成交量 | 672,817 |
| 平均成交量 (3个月) | 876,560 |
| 市值 | 982,327,360 |
| 价格/销量 (P/S) | 3.11 |
| 股市价格/股市净资产 (P/B) | 1.52 |
| 52周波幅 | |
| 利润日期 | 30 Apr 2026 |
| 营业毛利率 | -10.92% |
| 营业利益率 (TTM) | 37.82% |
| 稀释每股收益 (EPS TTM) | -0.660 |
| 季度收入增长率 (YOY) | 646.20% |
| 总债务/股东权益 (D/E MRQ) | 1.59% |
| 流动比率 (MRQ) | 4.58 |
| 营业现金流 (OCF TTM) | -250.70 M |
| 杠杆自由现金流 (LFCF TTM) | -2.69 M |
| 资产报酬率 (ROA TTM) | -5.39% |
| 股东权益报酬率 (ROE TTM) | -7.34% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Arvinas, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
0.5
| 分析师共识 | 1.5 |
| 内部交易活动 | 1.5 |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.50 |
|
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 6.89% |
| 机构持股比例 | 90.98% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| New Leaf Venture Partners, L.L.C. | 30 Sep 2025 | 1,585,721 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 20.00 (Piper Sandler, 49.48%) | 购买 |
| 中 | 18.00 (34.53%) | |
| 低 | 11.00 (Wedbush, -17.79%) | 保留 |
| 平均值 | 17.20 (28.55%) | |
| 总计 | 4 购买, 1 保留 | |
| 平均价格@调整类型 | 13.07 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Citigroup | 05 Mar 2026 | 18.00 (34.53%) | 购买 | 13.72 |
| 06 Jan 2026 | 15.00 (12.11%) | 购买 | 11.83 | |
| Evercore ISI Group | 25 Feb 2026 | 19.00 (42.00%) | 购买 | 13.30 |
| Piper Sandler | 25 Feb 2026 | 20.00 (49.48%) | 购买 | 13.30 |
| Wedbush | 25 Feb 2026 | 11.00 (-17.79%) | 保留 | 13.30 |
| Barclays | 17 Dec 2025 | 18.00 (34.53%) | 购买 | 11.72 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BERKOWITZ NOAH | 13.38 | - | 45,000 | 602,100 |
| CACACE ANGELA M | 13.38 | - | 45,000 | 602,100 |
| HOUSTON JOHN G | - | 13.27 | -35,297 | -468,391 |
| LOOMIS DAVID K | 13.38 | - | 12,420 | 166,180 |
| MORRISON BRIGGS | 13.60 | - | 20,000 | 272,000 |
| SAIK ANDREW | 13.38 | - | 45,000 | 602,100 |
| TEEL RANDY | 13.38 | - | 147,791 | 1,977,444 |
| 累积净数量 | 279,914 | |||
| 累积净值 ($) | 3,753,532 | |||
| 累积平均购买 ($) | 13.42 | |||
| 累积平均卖出 ($) | 13.27 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| MORRISON BRIGGS | 董事 | 06 Mar 2026 | 买 (+) | 20,000 | 13.60 | 272,000 |
| HOUSTON JOHN G | 董事 | 27 Feb 2026 | 卖 (-) | 35,297 | 13.27 | 468,391 |
| TEEL RANDY | 职员 | 26 Feb 2026 | 获得 (+) | 147,791 | 13.38 | 1,977,444 |
| SAIK ANDREW | 职员 | 26 Feb 2026 | 获得 (+) | 45,000 | 13.38 | 602,100 |
| BERKOWITZ NOAH | 职员 | 26 Feb 2026 | 获得 (+) | 45,000 | 13.38 | 602,100 |
| CACACE ANGELA M | 职员 | 26 Feb 2026 | 获得 (+) | 45,000 | 13.38 | 602,100 |
| LOOMIS DAVID K | 职员 | 26 Feb 2026 | 获得 (+) | 12,420 | 13.38 | 166,180 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合